The Life Sciences logistics solutions provider, Biocair has recently expanded its operations into China. The opening ceremony, held on November 12th was attended by Carma Eliott, the British Consul General in Shanghai, who cut the ribbon together with Andy King, the Managing Director of Biocair. The British Consul general congratulated Biocair on the issue of their new Chinese Business Licence. She re-affirmed the British Government’s support of the Life Sciences sector and acknowledged the vital logistics role for research materials and clinical trial samples that Biocair can now provide companies in China.
Biocair, established since 1987, is a proven international specialist in transporting temperature sensitive biological materials and drugs for clinical trials in and out of the main pharmaceutical and biopharmaceutical clusters in UK, Europe, USA, South America, Russia, Japan, and India. The new logistics operation in Shanghai has extended their Asia service offering. Andy King commented; “This expansion into China is a key step in our international business development plan in response to growing customer demand in the region”. He went on to say: “We really appreciated all the encouragement and support we have had from customers, which helped us make this investment decision to enter the China market.”
Biocair used the consultancy company Asiasetup to assist in setting up operations in China. Asiasetup was able to gain ‘Wholly Foreign Owned Enterprise’ approval at Municipal level in two weeks and Biocair’s business license was granted two weeks later.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.